Background
Autologous neutralizing antibodies (aNAbs) can possibly delay viral rebound by targeting the HIV reservoir upon viral reactivation. We evaluated the immunogenicity of a mRNA-based therapeutic vaccine to boost aNAbs functionality and delay viral rebound after treatment interruption (ATI).
Methods
Fifteen rhesus macaques (RMs) were infected with a barcoded SHIV CH505.TF and treated with cART daily. After viral suppression, RMs were randomized into a vaccine group (n=8) that received HIV-1 CH505 gp160 trimers delivered by mRNA-LNP to elicit neutralizing antibodies targeting the CD4-binding site (bs) on envelope, and an unvaccinated control group (n=7). We tested plasma-purified IgG for neutralization in TZM-bl assay, and antibody-dependent cellular cytotoxicity (ADCC) using CH505TF gp120-coated and infected cells. We mapped Ab responses using electron microscopy-based polyclonal epitope mapping (EMPEM). We measured viral reservoir using the Intact Proviral DNA Assay (IPDA) and viremia by qPCR for 10 weeks after ATI. Exact Wilcoxon tests were used for analyses.
Results
Two weeks post-final immunization, the anti-CH505.TF aNAb levels were higher in the vaccine group (IC50 median:5.64 µg/mL, IQR: 3.16-11.22) than the control group [(median:33.98 µg/mL, IQR: 23.38-154.60), p=0.01]. CD4bs Abs indicative of CH235-like precursors based on plasma neutralization mapping in 6/8 RMs in the vaccine group compared to 1/7 in the control group. The vaccine group had higher median AUC for ADCC with gp120-coated target cells, albeit not significant (p = 0.38). ADCC undetectable against infected cells. The reservoir size was lower in the vaccine group (median: 0 copies/million cells; IQR: 0-1.95) compared to the control group 2.5 months after the last immunization before ATI (median: 3.41 copies/million cells; IQR: 3.29-4.17; p = 0.01). All RMs rebounded by 9 weeks post-ATI with no differences in time to rebound (vaccine: median 2 weeks, IQR 2-3; control: median 3 weeks, IQR 2-3; p = 0.14). However, the control group had higher AUC viral loads (VL) (p=0.014). Functional Ab responses did not correlate with VL after rebound. In the vaccine group, CD4bs Abs were present from pre-ATI and detectable until the last rebound measurement.
Conclusions
The vaccine regimen boosted aNAbs and ADCC responses, but all vaccinated RMs rebounded after ATI. These indicate need for immunization strategies beyond enhancing Ab functions, also focusing on the quality of epitope targeting to achieve control of viral rebound.